Bicocca Open Archive

Logo unimib boa
GAMBACORTI PASSERINI, CARLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 26.628
EU - Europa 11.831
AS - Asia 4.663
SA - Sud America 54
Continente sconosciuto - Info sul continente non disponibili 34
AF - Africa 30
OC - Oceania 16
Totale 43.256
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 26.204
IT - Italia 2.573
DE - Germania 2.191
IE - Irlanda 1.757
CN - Cina 1.699
SG - Singapore 1.671
SE - Svezia 1.574
RU - Federazione Russa 1.201
UA - Ucraina 988
HK - Hong Kong 583
GB - Regno Unito 556
CA - Canada 419
FI - Finlandia 290
VN - Vietnam 185
TR - Turchia 175
IN - India 169
FR - Francia 158
DK - Danimarca 117
BE - Belgio 95
ID - Indonesia 65
PL - Polonia 56
AT - Austria 54
NL - Olanda 53
BG - Bulgaria 32
EU - Europa 32
JP - Giappone 31
IR - Iran 28
CZ - Repubblica Ceca 26
KR - Corea 22
BR - Brasile 21
RO - Romania 19
CH - Svizzera 17
PT - Portogallo 13
AU - Australia 12
ES - Italia 12
GR - Grecia 12
LT - Lituania 11
CL - Cile 10
MU - Mauritius 10
NO - Norvegia 9
MY - Malesia 8
CO - Colombia 7
EG - Egitto 7
PE - Perù 7
AR - Argentina 6
SC - Seychelles 5
NZ - Nuova Zelanda 4
RS - Serbia 4
AM - Armenia 3
BD - Bangladesh 3
EC - Ecuador 3
TH - Thailandia 3
ZA - Sudafrica 3
A2 - ???statistics.table.value.countryCode.A2??? 2
EE - Estonia 2
HR - Croazia 2
JO - Giordania 2
KW - Kuwait 2
MK - Macedonia 2
PK - Pakistan 2
SA - Arabia Saudita 2
SK - Slovacchia (Repubblica Slovacca) 2
TN - Tunisia 2
TW - Taiwan 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
BA - Bosnia-Erzegovina 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
HN - Honduras 1
IQ - Iraq 1
KG - Kirghizistan 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MA - Marocco 1
MD - Moldavia 1
MX - Messico 1
MZ - Mozambico 1
NG - Nigeria 1
PH - Filippine 1
PR - Porto Rico 1
SI - Slovenia 1
UZ - Uzbekistan 1
YE - Yemen 1
Totale 43.256
Salva come PNG Salva come JPEG
Città #
Ann Arbor 6.174
Woodbridge 2.706
Fairfield 2.295
Dublin 1.713
Houston 1.600
Chandler 1.489
Frankfurt am Main 1.434
Wilmington 1.313
Ashburn 1.295
Singapore 1.287
Milan 1.063
Jacksonville 1.040
Seattle 921
Dearborn 794
Cambridge 784
New York 659
Santa Clara 647
Hong Kong 572
Princeton 564
Nanjing 315
Shanghai 266
Altamura 249
Lawrence 249
Beijing 222
Göttingen 188
Lachine 173
San Diego 137
Boardman 127
Guangzhou 115
Lissone 101
Toronto 100
Andover 98
Nanchang 95
Helsinki 94
Brussels 93
Dong Ket 91
Ottawa 88
Shenyang 88
Fremont 80
Hebei 68
Fürstenwalde 65
Jakarta 64
Tianjin 64
Romola 62
Munich 61
Jiaxing 56
Lodz 52
London 52
Los Angeles 51
Jinan 49
Falls Church 48
Vienna 47
Norwalk 46
Kocaeli 45
Changsha 43
Mountain View 42
Pune 41
Kunming 40
Rome 40
Redmond 37
Edmonton 35
Hangzhou 32
Huizen 31
Washington 30
Chicago 28
Hefei 28
Cinisello Balsamo 27
Kiev 26
Zhengzhou 24
Monza 23
Dallas 20
Moscow 20
Ningbo 20
Plovdiv 20
Bonndorf 19
Carate Brianza 19
Bologna 18
Pavia 18
Desio 16
Kilburn 16
Nürnberg 16
San Mateo 16
Turin 16
Bari 15
Como 15
Detroit 15
St Petersburg 15
Leawood 14
Sacramento 14
Brno 13
Monmouth Junction 13
Taizhou 13
University Park 13
Daejeon 12
Fuzhou 12
Hounslow 12
Lappeenranta 12
Philadelphia 12
Delhi 11
Meda 11
Totale 33.132
Salva come PNG Salva come JPEG
Nome #
De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways 401
Characterization of intra-host SARS-CoV-2 variants improves phylogenomic reconstruction and may reveal functionally convergent mutations 397
A bioinformatics procedure to identify and annotate somatic mutations in whole-exome sequencing data 359
Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer 354
VERSO: a comprehensive framework for the inference of robust phylogenies and the quantification of intra-host genomic diversity of viral samples 348
Wiskott–Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma 317
VERSO:A COMPREHENSIVE FRAMEWORK FOR THE INFERENCE OF ROBUST PHYLOGENIES AND THE QUANTIFICATION OF INTRA-HOST GENOMIC DIVERSITY OF VIRAL SAMPLES 314
Acute myeloid leukaemia niche regulates response to L-asparaginase 312
Imatinib Long-Term Effects Study: Global Independent Assessment of Imatinib in Chronic Myeloid Leukemia: Results At 8 Years 309
Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study 307
Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib 306
BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene 304
RNA-seq is a valuable complement of conventional diagnostic tools in newly diagnosed AML patients 303
Long-term efficacy and safety of crizotinib in relapsed ALK positive lymphoma patients: clinical and biological correlates 289
The Risk of Relapse in CML Patients Who Discontinued imatinib Can Be Predicted Based on Patients Age and the Results of dPCR Analysis 285
OncoScore: A novel, Internet-based tool to assess the oncogenic potential of genes 284
Erratum: OncoScore: a novel, Internet-based tool to assess the oncogenic potential of genes 275
A computational procedure to identify and annotate somatic mutations in next-generation sequencing data 272
Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency 270
ETNK1 MUTATIONS INCREASE MITOCHONDRIAL ACTIVITY AND PROMOTE DNA DAMAGE THROUGH ROS PRODUCTION 270
WHOLE-EXOME SEQUENCING OF A PHILADELPHIA NEGATIVE CHRONIC MYELOID LEUKEMIA PATIENT THROUGH THE EXON-CAPTURE TECHNIQUE 269
Chronic myeloid leukemia: Second-line drugs of choice 268
Imatinib long term effects study: three years of follow-up and assessment 267
Characterization of compound 584, an Abl kinase inhibitor with lasting effects 264
SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub 261
An Imatinib–non-responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization 260
ETNK1 mutations promote ROS production and DNA damage through increased mitochondrial activity 257
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib 256
ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine 252
Three novel patients derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors 242
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells 237
ETNK1 mutations in atypical chronic myeloid leukemia induce a mutator phenotype that can be reverted with phosphoethanolamine 237
Decitabine treatment for an unusual case of atypical chronic myeloid leukemia (aCML) with a concomitant chronic lymphocytic leukemia (CLL) 229
Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma 224
Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition 220
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia 219
Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors 215
Response to ‘D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients’ by leguay et al 211
BCR-ABL nuclear entrapment kills human CML cells: Ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B 209
In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib 208
Choosing the right TKI for chronic myeloid leukemia: when the truth lies in "long-term" safety and efficacy 206
NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma 204
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia 203
Evidence of ETNK1 Somatic Variants in Atypical Chronic Myeloid Leukemia 203
Recurrent ETNK1 mutations in atypical chronic myeloid leukemia 203
Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells 203
Identification of novel point mutations in splicing sites integrating whole-exome and RNA-seq data in myeloproliferative diseases 202
Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling 200
Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients 200
Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling 200
Gene expression signature of non-involved lung tissue associated with survival in lung adenocarcinoma patients 198
CEQer: A Graphical Tool for Copy Number and Allelic Imbalance Detection from Whole-Exome Sequencing Data 197
Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma 196
Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis 196
A fatal case of TEMPI syndrome, refractory to proteasome inhibitors and autologous stem cell transplantation 192
Integrated Genomic, Functional and Prognostic Characterization of Atypical Chronic Myeloid Leukemia (aCML) in a Cohort of 43 Patients 191
Highly sensitive mutations detection in BCR-ABL positive leukemia prior and during imatinib treatment 190
Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase 190
Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias 189
Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy 189
Abstract 902: In vitro andin vivocharacterization of resistance to lorlatinib treatment in ALK mutated cancers 189
Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors 187
Inhibition of RET tyrosine kinase by SU5416 187
Reply to P. Laneuville et al 187
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy 186
A New BCR-ABL1 Mutation (L248R) Is Highly Resistant to Imatinib, Bosutinib, Nilotinib and Dasatinib, but Can Be Inhibited by AP-24534 and DCC-2036 185
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia 185
Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY 184
Synthesis and biological evaluation of benzo[4,5]imidazo[1,2-c]pyrimidine and benzo[4,5]imidazo[1,2-a]pyrazine derivatives as anaplastic lymphoma kinase inhibitors 183
ALK inhibitors for clinical use in cancer therapy 182
Erratum: Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design (Journal of Medicinal Chemistry (2017) 60:22 (9205-9221) DOI: 10.1021/acs.jmedchem.7b01039) 181
Expression, purification, and inhibition of human RET tyrosine kinase 179
Integrated Analysis of Whole-Exome Sequencing and Micrornas Expression in Blast Crisis Transformation of Chronic Myeloid Leukemia 179
Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants 178
ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells 178
Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors 177
Evidence for D276G and L364I Bcr-Abl mutations in Ph plus leukaemic cells obtained from patients resistant to Imatinib 176
Epigenetic Silencing of the Proapoptotic Gene BIM in Anaplastic Large Cell Lymphoma through an MeCP2/SIN3a Deacetylating Complex 174
CML Patients Present Additional Mutations in Cancer Related Genes When Tested At Diagnosis 172
Oncoscore, a Novel, Internet-Based Tool to Assess the Oncogenic Potential of Genes Can Differentiate Between CP-CML and BC-CML Associated Genes, and Between CP-CML Patients with Good and Bad Prognosis 172
The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years 171
Deferasirox in the management of iron-overload in patients with myelofibrosis: a multicentre study from the Rete Ematologica Lombarda (IRON-M study) 169
BCR AND BCR-ABL REGULATION DURING MYELOID DIFFERENTIATION IN HEALTHY DONORS AND CHRONIC PHASE-BLAST CRISIS CML PATIENTS 168
Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes 168
Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019 168
Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation 166
ABL INHIBITOR BMS354825 BINDING MODE IN ABELSON KINASE REVEALED BY MOLECULAR DOCKING STUDIES 166
Recurrent KIT D816V Mutation in Atypical Chronic Myeloid Leukemia 165
Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis 165
Synergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cells 164
Valproic acid enhances bosutinib cytotoxicity in colon cancer cells 164
Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients 164
Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis 164
Whole-Exome Sequencing Data - Identifying Somatic Mutations 164
Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth 163
A rapid method for the purification of wild-type and V804M mutant ret catalytic domain: A tool to study thyroid cancer 162
First-line treatment of 102 chronic myeloid leukemia patients with imatinib: A long-term single institution analysis 162
Increased sFLT-1/PlGF ratio in COVID-19: A novel link to angiotensin II-mediated endothelial dysfunction 162
The ALK gene, an attractive target for inhibitor development 161
Whole-Exome Sequencing of 8 Atypical Chronic Myeloid Leukaemia Patients 161
Totale 21.951
Salva come PNG Salva come JPEG
Categoria #
all - tutte 150.281
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 150.281
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20205.138 0 0 0 0 699 857 1.101 611 736 474 492 168
2020/20217.402 336 311 901 756 605 687 780 698 650 650 473 555
2021/20224.093 331 406 499 279 276 366 213 228 206 304 329 656
2022/20236.561 864 1.919 566 554 469 932 72 333 418 126 152 156
2023/20245.361 129 146 202 235 671 1.456 978 159 443 287 90 565
2024/20254.557 790 1.498 734 665 870 0 0 0 0 0 0 0
Totale 45.007